{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:41Z","timestamp":1794011441115,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Suzhou Applied Basic Research (Healthcare) Science and Technology Innovation Project","award":["grant no. SYW2025134"],"award-info":[{"award-number":["grant no. SYW2025134"]}]},{"name":"National Natural Science Foundation International (Regional) Cooperation and Exchange Project","award":["Grant No.: 82220108003"],"award-info":[{"award-number":["Grant No.: 82220108003"]}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Plan","doi-asserted-by":"crossref","award":["Project No.: Guike AB21196024"],"award-info":[{"award-number":["Project No.: Guike AB21196024"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018571","name":"Guangxi Science and Technology Base and Talent Special Project","doi-asserted-by":"crossref","award":["Project No.: Guike AD20238062"],"award-info":[{"award-number":["Project No.: Guike AD20238062"]}],"id":[{"id":"10.13039\/501100018571","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01821-7","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:35:31Z","timestamp":1782977731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment"],"prefix":"10.1186","volume":"19","author":[{"given":"Yangzi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenxia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhen","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"1821_CR1","doi-asserted-by":"crossref","unstructured":"Darrell J, Irvine et al. The future of engineered immune cell therapies.Science. 2022;378(6622):853\u201385.","DOI":"10.1126\/science.abq6990"},{"issue":"7","key":"1821_CR2","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.7150\/thno.106999","volume":"5","author":"S Wu","year":"2025","unstructured":"Wu S, Wang Q, Du J, et al. A p-n heterojunction sonosensitizer for improved sono-immunotherapy via induction of multimodal cell death mechanisms. Theranostics. 2025;5(7):2737\u201356.","journal-title":"Theranostics"},{"key":"1821_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther. 2025;10:210.","journal-title":"Sig Transduct Target Ther"},{"key":"1821_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu Q, Zhu Y, Mei J, et al. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 2025;18:65.","journal-title":"J Hematol Oncol"},{"key":"1821_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","volume":"6","author":"R Jin","year":"2025","unstructured":"Jin R, Neufeld L, McGaha TL. Linking macrophage metabolism to function in the tumor microenvironment. Nat Cancer. 2025;6:239\u201352.","journal-title":"Nat Cancer"},{"key":"1821_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17:105.","journal-title":"J Hematol Oncol"},{"key":"1821_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-025-02225-w","volume":"24","author":"L Zhao","year":"2025","unstructured":"Zhao L, Gui Y, Cai J, et al. Biometallic ions and derivatives: a new direction for cancer immunotherapy. Mol Cancer. 2025;24:17.","journal-title":"Mol Cancer"},{"issue":"1","key":"1821_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target therapy. 2024;9(1):274.","journal-title":"Signal Transduct Target therapy"},{"key":"1821_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","volume":"635","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis F, Araujo HA, Do MT, et al. CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024;635:462\u201371.","journal-title":"Nature"},{"issue":"24","key":"1821_CR10","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson DJ, Eroglu Z, Brockstein B, et al. Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J Clin Oncol. 2021;39(24):2647\u201355.","journal-title":"J Clin Oncol"},{"key":"1821_CR11","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56:2388-2407.e9.","journal-title":"Immunity"},{"issue":"1","key":"1821_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"key":"1821_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100718","volume":"53","author":"E P\u00e9rez-Ruiz","year":"2020","unstructured":"P\u00e9rez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, et al. Cancer immunotherapy resistance based on immune checkpoints inhibitors: targets, biomarkers, and remedies. Drug Resist Updat. 2020;53:100718.","journal-title":"Drug Resist Updat"},{"key":"1821_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41586-025-09303-5","volume":"645","author":"J Heide","year":"2025","unstructured":"Heide J, Bilecz AJ, Patnaik S, et al. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025;645:1051\u20139.","journal-title":"Nature"},{"issue":"2","key":"1821_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang LC, Lo A, Scholler J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunology Research. 2014;2(2):154\u201366.","journal-title":"Cancer Immunology Research"},{"key":"1821_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1821_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun JW, Yoon JH, Ahn HR, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (Lond). 2023;43(4):455\u201379.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"1821_CR18","doi-asserted-by":"publisher","first-page":"2007017","DOI":"10.1002\/adfm.202007017","volume":"31","author":"S Zhou","year":"2021","unstructured":"Zhou S, Zhen Z, Paschall AV, et al. FAP-Targeted Photodynamic Therapy Mediated by Ferritin Nanoparticles Elicits an Immune Response against Cancer Cells and Cancer Associated Fibroblasts. Adv Funct Mater. 2021;31(7):2007017.","journal-title":"Adv Funct Mater"},{"issue":"9","key":"1821_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1821_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","volume":"8","author":"YJ Xie","year":"2020","unstructured":"Xie YJ, Dougan M, Ingram JR, et al. Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. Cancer Immunol Res. 2020;8(4):518\u201329.","journal-title":"Cancer Immunol Res"},{"key":"1821_CR21","doi-asserted-by":"crossref","unstructured":"Wang LC, Lo A, Scholler J et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2(2):154\u201366.","DOI":"10.1158\/2326-6066.CIR-13-0027"},{"issue":"12","key":"1821_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"key":"1821_CR23","doi-asserted-by":"crossref","unstructured":"Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A; 2013.","DOI":"10.1073\/pnas.1320318110"},{"key":"1821_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-023-01507-4","volume":"16","author":"Z Ding","year":"2023","unstructured":"Ding Z, Sun S, Wang X, et al. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression. J Hematol Oncol. 2023;16:115.","journal-title":"J Hematol Oncol"},{"key":"1821_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41392-021-00462-1","volume":"6","author":"F Mo","year":"2021","unstructured":"Mo F, Duan S, Jiang X, et al. Nanobody-based chimeric antigen receptor T cells designed by CRISPR\/Cas9 technology for solid tumor immunotherapy. Sig Transduct Target Ther. 2021;6:80.","journal-title":"Sig Transduct Target Ther"},{"issue":"8","key":"1821_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"C MMunshi, Nikhil","year":"2021","unstructured":"MMunshi, Nikhil C, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"1821_CR27","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","volume":"8","author":"Z Xia","year":"2024","unstructured":"Xia Z, Jin Q, Long Z, et al. Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders. Nat Biomed. 2024;8:1634\u201350.","journal-title":"Nat Biomed"},{"key":"1821_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, et al. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2:904\u201318.","journal-title":"Nat Cancer"},{"key":"1821_CR29","doi-asserted-by":"crossref","unstructured":"Murad JP, Christian L, Rosa R et al. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng. 2026;10(4):613\u201329.","DOI":"10.1038\/s41551-025-01509-2"},{"key":"1821_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku O, Jackson H, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechno. 2018;36:847\u201356.","journal-title":"Nat Biotechno"},{"issue":"25","key":"1821_CR31","doi-asserted-by":"publisher","first-page":"e2308265","DOI":"10.1002\/smll.202308265","volume":"20","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen J, Zhang S, et al. Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors. Small. 2024;20(25):e2308265.","journal-title":"Small"},{"key":"1821_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40164-025-00621-y","volume":"14","author":"MA Saliu","year":"2025","unstructured":"Saliu MA, Wang Q, Salisu MD, et al. Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer. Exp Hematol Oncol. 2025;14:27.","journal-title":"Exp Hematol Oncol"},{"key":"1821_CR33","doi-asserted-by":"crossref","unstructured":"Liu X, Le Gall C, Alexander RK et al. Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy. Nat Biomed Eng. 2026;10(1):39\u201355.","DOI":"10.1038\/s41551-025-01447-z"},{"issue":"14","key":"1821_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024;390(14):1290\u20138.","journal-title":"N Engl J Med"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01821-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01821-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01821-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:07:32Z","timestamp":1788275252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01821-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01821-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Guangxi Medical University and Union Hospital, Xiehe Medical College, Huazhong University of Science and Technology, and was conducted in accordance with the Declaration of Helsinki principles. All patients provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and\u00a0<b>consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"65"}}